MedTrace Logo

A Clinical Study to Examine the Drug-drug Interactions Between ACT-541468 and Citalopram in Healthy Male and Female Subjects

NCT03907215 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2019-10-31

No results posted yet for this study

Summary

A clinical study to examine the drug-drug interactions between ACT-541468 and citalopram in healthy male and female subjects

Conditions

  • Healthy

Interventions

DRUG

ACT541468

50 mg; film-coated tablet for oral use

DRUG

ACT541468 placebo

film-coated tablet for oral use

DRUG

Citalopram

20 mg; tablet tor oral use; for single- or repeated dosing

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Idorsia Pharmaceuticals Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
24 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-09
Primary Completion
2019-06-26
Completion
2019-06-26
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03907215 on ClinicalTrials.gov